Home
Diseases
Type 1 Diabetes

Type 1 Diabetes

Disease

Disease Profile

Type 1 diabetes is a chronic autoimmune disease in which the immune system destroys insulin-producing beta cells, resulting in absolute insulin deficiency and lifelong insulin replacement needs.

Category: Endocrine, nutritional and metabolic diseases
Prevalence: About 2 million Americans, including about 304,000 youth under age 20

ICD Codes

Related News

Living Insulin Implant Shows Promise as Millions Still Lack Access to Diabetes Medication

Jun 29, 2026

A living insulin implant from Technion researchers achieved one year of steady blood sugar control in diabetic mice, while millions worldwide still lack access to insulin medication. Animal trials showed beta cells could auto-dose insulin, though immune barriers remain before human trials. Meanwhile, only about half of type 2 diabetes patients globally have access to needed insulin, with the problem affecting both low- and high-income countries.

CD27 Expression Identified as Key Marker for Monitoring Treg Therapy Efficacy

Jun 25, 2026

Research has identified CD27 expression as a potential biomarker for monitoring regulatory T cell (Treg) induction efficacy in clinical trials. Studies show CD27 marks memory-like Tregs with superior suppressive capacity, correlating with immune regulation in type 1 diabetes patients. Treg-based tolerance restoration is emerging as a therapeutic strategy for autoimmune diseases and transplantation.

Sequel's twiist AID System Shows Significant Blood Sugar Improvements in Type 2 Diabetes Trial

Jun 08, 2026

Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.

Tandem Diabetes Wins CE Mark for AID Systems in Europe After FDA Pregnancy Approval

Jun 05, 2026

Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.

Diabetes Tech Companies Launch Enhanced CGM Systems and Insulin Delivery Platforms

Jun 04, 2026

Diabetes technology companies Dexcom, Insulet, and Sequel/Senseonics announced major product launches and algorithm updates. Dexcom is acquiring Nutrisense and launching an enhanced Stelo app, Insulet is rolling out an updated Omnipod 5 algorithm with lower glucose targets and Abbott compatibility, and Sequel/Senseonics have fully launched the Eversense 365 CGM with the twiist insulin delivery system in the U.S.

MannKind Wins FDA Approval for Afrezza Inhaled Insulin in Children Ages 6 and Older

May 31, 2026

MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.

MannKind's Afrezza Inhaled Insulin Approved for Children; Updated Label Provides New Dose Guidance for Adults

May 30, 2026

FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.

C-peptide Seen as Key Biomarker for Type 1 Diabetes Drug Trials

May 03, 2026

C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.

First AAV gene therapy trial for type 1 diabetes to begin this year

Apr 23, 2026

The first clinical trial of an AAV gene therapy for type 1 diabetes is set to begin this year. The 52-week phase 1 PROGRESS study will test one-time intramuscular KRIYA-839 in adults with A1c above 7% using automated insulin delivery systems.

Evidence on ketogenic diets remains mixed across mental health, diabetes, and PCOS

Apr 21, 2026

Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07596160	Individualized Exercise Consultation in Type 1 Diabetes	NOT_YET_RECRUITING	NA
NCT07594145	Precision T1D Platform - New Therapies for Cardio-Renal Complications	NOT_YET_RECRUITING	PHASE2
NCT07593625	Evaluating Glucose Control Using a Next-Generation AID Algorithm in Adults With T1D	NOT_YET_RECRUITING	NA
NCT07593105	Oat Flakes β-glucan on Glycemic Variability, Pancreatic Reserve, and Dyslipidemia Among Adolescents With Type 1 Diabetes	COMPLETED	NA
NCT07591077	SGLT2 Adjunct in T1D	COMPLETED	PHASE2/PHASE3
NCT07573228	Impact of Obesity on Microvascular Insulin Action and Cardiorespiratory Fitness in Type 1 Diabetes	RECRUITING	NA
NCT07564752	The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 Diabetes	RECRUITING
NCT07560813	NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes	NOT_YET_RECRUITING	NA
NCT07550608	Effects of Pre-Exercise Basal Insulin Manipulation on Glucose Dynamics in Females vs. Males With Type 1 Diabetes	COMPLETED	NA
NCT07501338	Early Automated Insulin Delivery (AID) Pilot for Newly Diagnosed T1D	NOT_YET_RECRUITING	NA